

KING PHARMACEUTICALS INC

Form 8-K

April 29, 2003

**Table of Contents**

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 25, 2003

**King Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Tennessee**  
(State or other jurisdiction  
of incorporation)

**0 24425**  
(Commission  
File Number)

**54-1684963**  
(IRS Employer  
Identification Number)

**501 Fifth Street, Bristol, Tennessee**  
(Address of principal executive offices)

**37620**  
(Zip Code)

Registrant's telephone number, including area code: **423-989-8000**

Not Applicable  
(Former name or former address, if changed since last report)

---

---

**TABLE OF CONTENTS**

SIGNATURE

Exhibit Index

EX-99.1 PRESS RELEASE

---

**Table of Contents**

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits**

(a) Financial Statements on Businesses Acquired.

None.

(b) Pro Forma Financial Information.

None.

(c) Exhibits.

The following exhibits are filed pursuant to Item 601 of Regulation S-K:

**Exhibits:**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release of King Pharmaceuticals, Inc. dated April 25, 2003.

**Item 9. Regulation FD Disclosure**

On April 25, 2003, King Pharmaceuticals, Inc., a Tennessee corporation, issued a press release which provided a preview of its first quarter 2003 financial results and which announced King's plans to release its first quarter 2003 results on May 6, 2003.

In accordance with the Securities and Exchange Commission (the "SEC") Release No. 34-47583 and the General Instructions B.2. and B.6. of Form 8-K, the information contained in this report, which is intended to be furnished under Item 12, Results of Operations and Financial Condition, is instead being furnished under Item 9, Regulation FD Disclosure. This information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 29, 2003

KING PHARMACEUTICALS, INC.

By: /s/ James R. Lattanzi  
James R. Lattanzi  
Chief Financial Officer

---

**Table of Contents**

**Exhibit Index**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release of King Pharmaceuticals, Inc. dated April 25, 2003.